BLTE Company Profile and Key Details

BLTE has shown sold momentum, gaining 3.37% over the past week and 82.43% over the past quarter, though year-to-date performance is up 0.03%. Short-term trend indicators are bearishly aligned (SMA20 4.9%, SMA50 13.15%, SMA200 85.16%). The stock’s 14-day RSI is 64.81 (firm momentum), while the ATR of 8.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.72% below its high and over 284.8% above its low. Average 10-day trading volume of 70.87 thousand shares is below the 3-month average of 165.20 thousand, indicating normal recent market interest.

Belite Bio, Inc has 32.83 million shares outstanding. The public float is 15.17 million shares, elevated short interest at 1.18% of float. This equals 180.33 thousand shares. The short ratio is 3.89 days. Institutional investors hold 1.6% of the float. Insiders own 53.45%. Lin Yu-Hsin holds 170.93 thousand shares, Chuang Hao-Yuan has 93.80 thousand shares and Chen Wan-Shan has 9.10 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.31 thousand shares across 15 transactions.

Belite Bio, Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.51. This means the shares are trading above this model’s fair value.

Belite Bio, Inc generated EPS of -$1.92 over the past year. Five-year average earnings growth is -777.09%. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.55. Next year's EPS is expected at $43.48. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $266.00 to $98.00. The high target offers 67.13% upside. The low target suggests -38.43% downside. The mean target is $173.73. This offers 9.15% upside. Belite Bio, Inc earnings surprise history is a mixed track record. The quarter that ended March 02, 2026, missed forecasts by -32.14%. The prior quarter beat by 22.64%. Over the last six quarters, Apple has recorded several small beats. These include -6.67% in November 12, 2024.

Belite Bio, Inc (NASDAQ:BLTE) closed at $154.85 USD, losing -$4.31 (-2.71%) from the previous close of $159.16. The stock is currently mid-range between its 52-week high and low $56.10 and $200.00. With a market capitalization of about $6.19 billion, Belite Bio, Inc is classified as a mid-cap and shows lower-than-market volatility (beta ~-1.22). Key stats such as the average daily volume over the past year has been around 163.60 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Belite Bio, Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yu-Hsin Lin, the company employs approximately 25 people and listed since April 29, 2022. Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases.

Belite Bio, Inc trades at a P/E ratio of -66.92, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.74 trading at moderately above to book value. The P/FCF stands at -585.88, also below market averages.

Our AI price prediction model suggests that Belite Bio, Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.41%, with price expected at $158.50 by May 14, 2026, within a range of $149.36 to $167.55 3-Month Outlook: Projected rise of 43.77%, reaching $228.83 by July 29, 2026, with a range of $227.26 to $230.76. 1-Year Outlook: Projected gain of 27.72%, with price at $203.28 by April 30, 2027, within a range of $194.56 to $212.39.

Belite Bio, Inc (NASDAQ:BLTE) shares are flat 0.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Belite Bio, Inc trading at a premium to the broader market with a P/E of -66.92. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $111.53, suggesting -29.93% downside. Our AI forecast model points to short-term weakness (-0.41% over two weeks), a medium-term rise (43.77% over three months), and a longer-term gain (27.72% over one year), with expected trading ranges indicating moderate volatility.